Items where Author is "Albersen, Maarten"

Journal Article

Milenkovic, Uros and Boeckx, Bram and Lambrechts, Diether and Janky, Rekin’s and Hatzichristodoulou, Georgios and van Renterghem, Koen and Gevaert, Thomas and Cellek, Selim and Bivalacqua, Trinity J. and De Ridder, Dirk and Albersen, Maarten (2021) Single-cell Transcriptomics Uncover a Novel Role of Myeloid Cells and T-lymphocytes in the Fibrotic Microenvironment in Peyronie’s Disease. European Urology Focus. ISSN 2405-4569

Weyne, Emmanuel and Ilg, Marcus M. and Cakir, Onur Omer and Muneer, Asif and Roussel, Delphine Behr and Albersen, Maarten and Angulo, Javier and Corona, Giovanni and Bettocchi, Carlo and Reisman, Yacov and Castiglione, Fabio (2020) European Society for Sexual Medicine Consensus Statement on the Use of the Cavernous Nerve Injury Rodent Model to Study Postradical Prostatectomy Erectile Dysfunction. Sexual Medicine, 8 (3). pp. 327-337. ISSN 2050-1161

Milenkovic, Uros and Ilg, Marcus M. and Cellek, Selim and Albersen, Maarten (2019) Pathophysiology and Future Therapeutic Perspectives for Resolving Fibrosis in Peyronie’s Disease. Sexual Medicine Reviews, 7 (4). pp. 679-689. ISSN 2050-0521

Milenkovic, Uros and Ilg, Marcus M. and Zuccato, Carola and Ramazani, Yasaman and De Ridder, Dirk and Albersen, Maarten (2019) Simvastatin and the Rho-kinase inhibitor Y-27632 prevent myofibroblast transformation in Peyronie's disease-derived fibroblasts via inhibition of YAP/TAZ nuclear translocation. BJU International, 123 (4). pp. 703-715. ISSN 1464-410X

Milenkovic, Uros and Ilg, Marcus M. and Cellek, Selim and Albersen, Maarten (2019) What role do pharmaceuticals play in the treatment of Peyronie’s disease and is there a need for new emerging drugs? Expert Opinion on Emerging Drugs, 24 (1). pp. 1-4. ISSN 1472-8214

Ilg, Marcus M. and Mateus, Marta and Stebbeds, William J. and Milenkovic, Uros and Christopher, Nim and Muneer, Asif and Albersen, Maarten and Ralph, David J. and Cellek, Selim (2019) Antifibrotic synergy between phosphodiesterase type 5 inhibitors and selective oestrogen receptor modulators in Peyronie’s disease models. European Urology, 75 (2). pp. 329-340. ISSN 1873-7560